Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 18/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL501974 | 1.00 | NOTUM (0.39) | NOTUMMDM2CYP1A2 | |
| SCHEMBL3946497 | 1.00 | NOTUM (0.39) | NOTUMMDM2CYP1A2 | |
| SCHEMBL20853553 | 0.96 | NOTUM (0.36) | NOTUMMDM2CYP1A2 | |
| SCHEMBL3835696 | 0.95 | NOTUM (0.41) | NOTUM | |
| SCHEMBL502154 | 0.95 | NOTUM (0.41) | NOTUM | |
| SCHEMBL3481434 | 0.95 | NOTUM (0.41) | NOTUM | |
| SCHEMBL502155 | 0.95 | NOTUM (0.41) | NOTUM | |
| SCHEMBL502501 | 0.94 | NOTUM (0.35) | NOTUMMDM2 | |
| SCHEMBL4255728 | 0.94 | NOTUM (0.35) | NOTUMMDM2 | |
| SCHEMBL502502 | 0.94 | NOTUM (0.35) | NOTUMMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906652-B2 | Heterocycle-substituted 3-alkyl azetidine derivatives | MERCK SHARP & DOHME CORP. (US) | 2011-03-15 | — | — | US | claimed |
| US-20100081642-A1 | CB-1 RECEPTOR MODULATOR PHARMACEUTICAL FORMULATIONS | MERCK SHARP & DOHME CORP. | 2010-04-01 | — | — | US | claimed |
| US-20070123505-A1 | Heterocycle-substituted 3-alkyl azetidine derivatives | MERCK SHARP & DOHME CORP. | 2007-05-31 | — | — | US | claimed |
| EP-3243385-B1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-2888006-B1 | NOVEL AZABENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES USEFUL AS AMPK ACTIVATORS | MERCK SHARP & DOHME (US) | 2019-04-24 | — | — | EP | disclosed |
| US-9868733-B2 | Azabenzimidazole tetrahydrofuran derivatives | MERCK SHARP & DOHME CORP. (US) | 2018-01-16 | — | — | US | disclosed |
| EP-3243385-A1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | Merck Sharp & Dohme Corp. (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2677869-B1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME (US) | 2017-11-08 | — | — | EP | disclosed |
| US-9593155-B2 | Oxyntomodulin analogs | MERCK SHARP & DOHME CORP. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9556193-B2 | Benzimidazole hexahydrofuro[3,2-b]furan derivatives | Merck Shapr & Dohme Corp. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9540364-B2 | Benzimidazole tetrahydrofuran derivatives | MERCK SHARP & DOHME CORP. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20090104210-A1 | Peptide compounds for treating obesity and insulin resistance | MERCK SHARP & DOHME CORP. | 2009-04-23 | — | — | US | disclosed |
| US-20080269279-A1 | Substituted furo[2,3-B] pyridine derivatives as cannabinoid-1 receptor modulators | MERCK SHARP & DOHME CORP. | 2008-10-30 | — | — | US | disclosed |
| US-20080207666-A1 | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators | MERCK SHARP & DOHME CORP. | 2008-08-28 | — | — | US | disclosed |
| US-20080085926-A1 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME LLC | 2008-04-10 | — | — | US | disclosed |
| US-20070244048-A1 | Neuromedin U receptor agonists and uses thereof | MERCK SHARP & DOHME CORP. | 2007-10-18 | — | — | US | disclosed |
| WO-2007064566-A2 | HETEROCYCLE-SUBSTITUTED 3-ALKYL AZETIDINE DERIVATIVES | MERCK & CO., INC. (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20070123505-A1 | Heterocycle-substituted 3-alkyl azetidine derivatives | MERCK SHARP & DOHME CORP. | 2007-05-31 | — | — | US | disclosed |
| US-20070123505-A1 | Heterocycle-substituted 3-alkyl azetidine derivatives | MERCK SHARP & DOHME CORP. | 2007-05-31 | — | — | US | disclosed |
| US-20070123505-A1 | Heterocycle-substituted 3-alkyl azetidine derivatives | MERCK SHARP & DOHME CORP. | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269279-A1 | Substituted furo[2,3-B] pyridine derivatives as cannabinoid-1 receptor modulators | CNR1, CNR2, FAAH | NOTUM 1690/4885MDM2 3829/4885CYP1A2 689/4885 |
| US-20070123505-A1 | Heterocycle-substituted 3-alkyl azetidine derivatives | CNR1, CNR2, FAAH | NOTUM 2413/4885MDM2 3968/4885CYP1A2 433/4885 |
| US-20080085926-A1 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | GCGR, GLP1R, GPR119 | NOTUM 2351/4885MDM2 3617/4885CYP1A2 1996/4885 |
| US-20080207666-A1 | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators | CNR1, CNR2, FAAH | NOTUM 3054/4885MDM2 3602/4885CYP1A2 665/4885 |
| US-20100081642-A1 | CB-1 RECEPTOR MODULATOR PHARMACEUTICAL FORMULATIONS | CNR1, CNR2, GPBAR1 | NOTUM 1240/4885MDM2 3678/4885CYP1A2 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.